Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Feb 19;14(4):1385.
doi: 10.3390/jcm14041385.

Comprehensive Review of Endometrial Cancer: New Molecular and FIGO Classification and Recent Treatment Changes

Affiliations
Review

Comprehensive Review of Endometrial Cancer: New Molecular and FIGO Classification and Recent Treatment Changes

Maria-Bianca Anca-Stanciu et al. J Clin Med. .

Abstract

Endometrial cancer (EC) is the most common gynecologic malignancy in developed countries, with rising incidence due to aging populations and obesity-related factors. This review explores the evolving molecular and FIGO classifications of EC, highlighting their significance in diagnosis, prognosis, and personalized treatment strategies. Molecular subtyping based on The Cancer Genome Atlas (TCGA) classification offers a more precise understanding of EC, dividing it into POLE ultramutated, microsatellite instability-high (MSI-H), copy-number low (CNL), and copy-number high (CNH) subtypes. Each subgroup has distinct genetic, histological, and prognostic characteristics. Recent updates to the FIGO staging system incorporate molecular features, allowing for more tailored treatment approaches. Advances in immunotherapy, targeted therapies, and novel therapeutic combinations have reshaped clinical management. This review emphasizes the integration of molecular diagnostics into routine practice, outlining challenges and future perspectives in managing EC for improved patient outcomes.

Keywords: FIGO classification; POLE ultramutated; The Cancer Genome Atlas (TCGA); copy-number high (CNH); copy-number low (CNL); endometrial cancer; immunotherapy; microsatellite instability-high (MSI-H); molecular classification; personalized medicine; targeted therapies.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Algorithm of diagnostic in EC.

References

    1. Accorsi G.S., Paiva L.L., Schmidt R., Vieira M., Reis R., Andrade C. Sentinel lymph node mapping vs systematic lymphadenectomy for endometrial cancer: Surgical morbidity and lymphatic complications. J. Minim. Invasive Gynecol. 2020;27:938–945. doi: 10.1016/j.jmig.2019.07.030. - DOI - PubMed
    1. Wedin M., Stålberg K., Marcickiewicz J., Ahlner E., Åkesson Å., Lindahl G., Kjølhede P., LASEC Study Group Incidence of lymphedema in the lower limbs and lymphocyst formation within one year of surgery for endometrial cancer: A prospective longitudinal multicenter study. Gynecol. Oncol. 2020;159:201–208. doi: 10.1016/j.ygyno.2020.07.014. - DOI - PubMed
    1. Mitric C., Matanes E., Wissing M., Amajoud Z., Abitbol J., Yasmeen A., López-Ozuna V., Eisenberg N., Laskov I., Lau S., et al. The impact of wait times on oncological outcome in high-risk patients with endometrial cancer. J. Surg. Oncol. 2020;122:306–314. doi: 10.1002/jso.25929. - DOI - PubMed
    1. Makker V., MacKay H., Ray-Coquard I., Levine D.A., Westin S.N., Aoki D., Oaknin A. Endometrial cancer. Nat. Rev. Dis. Primers. 2021;7:88. doi: 10.1038/s41572-021-00324-8. - DOI - PMC - PubMed
    1. Brüggmann D., Ouassou K., Klingelhöfer D., Bohlmann M.K., Jaque J., Groneberg D.A. Endometrial cancer: Mapping the global landscape of research. J. Transl. Med. 2020;18:386. doi: 10.1186/s12967-020-02554-y. - DOI - PMC - PubMed

LinkOut - more resources